**General Aspects of Ozone Therapy**

Ruhi Cakir

[179] Morales NP, Charlermchoung C, Luechapudiporn R, Yamanont P, Fucharoen S, Chantharaksri U. Lipid Fluidity at Different Regions in LDL and HDL of beta-Tha‐ lassemia/Hb E Patients. Biochemical and Biophysical Research Communication

[180] Matayatsuk C, Poljak A, Bustamante S, Smythe GA, Kalpravidh RW, Sirankapracha P, et al. Quantitative Determination of ortho- and meta-Tyrosine as Biomarkers of Protein Oxidative Damage in beta-Thalassemia. Redox Report 2007;12(5) 219-228 [181] Phumala Morales N, Cherlermchoung C, Fucharoen S, Chantharaksri U. Paraoxo‐ nase and Platelet-Activating Factor Acetylhydrolase Activities in Lipoproteins of be‐ ta-Thalassemia/Hemoglobin E Patients. Clinical Chemistry and Laboratory Medicine

[182] Matayatsuk C, Lee CY, Kalpravidh RW, Sirankapracha P, Wilairat P, Fucharoen S, et al. Elevated F2-Isoprostanes in Thalassemic Patients. Free Radical Biology and Medi‐

[183] Palasuwan A, Kittisakulrat T, Amornrit W, Soogarun S, Wiwanitkit V, Pradniwat P. Antioxidant in Plasma of Hemoglobin-E Trait. Southeast Asian Journal of Tropical

[184] Somparn N, Kukongviriyapan U, Tassaneeyakul W, Jetsrisuparb A, Kukongviriya‐ pan V. Modification of CYP2E1 and CYP3A4 Activities in Haemoglobin E-beta Tha‐ lassemia Patients. European Journal of Clinical Pharmacology 2007;63(1) 43-50 [185] Senggunprai L, Kukongviriyapan U, Jetsrisuparb A, Kukongviriyapan V. Drug Me‐ tabolizing Enzyme CYP1A2 Status in Pediatric Patients with Hemoglobin E-beta Thalassemia. Journal of the Medical Association of Thailand 2009;92(12) 1675-1680

Medicine and Public Health 2005;36 Supplement 4 271-273

2006;350(3) 698-703

158 Pharmacology and Nutritional Intervention in the Treatment of Disease

2007;45(7) 884-889

cine 2007;43(12) 1649-1655

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/57470
